Aethlon Medical (NASDAQ: $AEMD) Research/Media Alert: “Expect Focus on Oncology Studies; Cost
Containment Efforts”
December 4, 2023 - Investorideas.com (https://www.investorideas.com) a global investor news source covering biotech and medical technology stocks
releases a research/media alert for investors following the sector, featuring
medical therapeutic company, Aethlon Medical, Inc. (NASDAQ:AEMD). Zacks
small-cap research issued a summary of
the report, ’Expect Focus on Oncology Studies; Cost Containment Efforts,’ on
November 16th.
Link to news/report
https://finance.yahoo.com/news/aemd-expect-focus-oncology-studies-160600342.html
Read the full research report
https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_11162023_AEMD_Marin.pdf
Read this news, featuring AEMD in full at https://www.investorideas.com/news/2023/biotech/12041Aethlon-Medical-AEMD-Oncology-Studies.asp
Excerpt:
By M. Marin
Expect no disruption from management change; increased emphasis on
studying Hemopurifier® in oncology likely…
Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO.
We expect no disruption as a result of the management change – Mr. Frakes has
been with Aethlon since 2008 & knows the company well, in our view.
Moreover, including Aethlon, he has had 27 years of CFO level financial
responsibility with publicly traded companies. We anticipate increased emphasis
on studying the Hemopurifier® in the oncology area, as well as potential cost
containment measures when possible, are likely.
Mr. Frakes, who was also appointed as a member of the company's board,
will continue his responsibilities as CFO. In addition, Guy Cipriani has been
named as the company's Chief Operating Officer. He had been Aethlon’s Chief
Business Officer prior to assuming the COO role. Mr. Cipriani has resigned from
the Aethlon board. We do not anticipate major changes as a result of this
management shift, although we believe the company is likely to emphasize its
clinical efforts in the field of oncology.
… and potential cost containment measures when possible…
Mr. Frakes has been with Aethlon since January 2008 and therefore knows
the company well, in our view. Moreover, including his role at Aethlon, he has
had 27 years of CFO level financial responsibility with publicly traded
companies, as noted. We do not anticipate a major shift in strategy as a result
of this management change, as noted, other than likely increased emphasis on
studying the Hemopurifier® in the oncology area and potential cost containment
efforts when possible.
Expect cash balance, lowering costs where possible, plus accessing ATM
funding will enable company to continue moving Hemopurifier forward towards
potential regulatory approval, commercialization
We believe lowering costs where possible, plus accessing funding, will enable
the company to continue moving the Hemopurifier forward in clinical studies
towards potential regulatory approval and commercialization. Under James
Frakes’ leadership as CFO, the company put in place an ATM (At The Market
offering) to enhance its financial flexibility. AEMD believes its cash balance
is sufficient to fund operations for at least a year. We believe lowering costs
where possible, plus accessing ATM funding, will enable the company to continue
moving the Hemopurifier forward in clinical studies towards potential
regulatory approval and commercialization. If Aethlon can demonstrate the
Hemopurifier’s ability to improve outcomes of cancer patients suffering from a
variety of different cancer types, we would anticipate strong commercial prospects
for the device.
… majority of patients treated with checkpoint inhibitors do not
respond; studying whether Hemopurifier with checkpoint inhibitors can improve
overall patient outcomes
The company recently received clearance from the Drug Controller General
of India (DCGI), which is India’s central drug authority, to conduct a phase 1
safety, feasibility and dose-finding trial of the Hemopurifier® in patients
with solid tumors who have stable or progressive disease during anti-PD-1
monotherapy treatment such as Keytruda® or Opdivo®. PD-1, or Programmed Cell
Death Protein 1, is a protein found on the cell surface that plays a role in
inhibiting immune responses. Treatment such as Keytruda®, a type of
immunotherapy, helps to block the PD-1 pathway to prevent cancer cells from
hiding and, in turn, help the immune system work. While Keytruda® and other
anti-PD-1 monotherapy treatments represent a substantial advance in cancer
treatment, with certain tumor types it does not work on the majority of cancer patients.
Checkpoint inhibitors such as Keytruda have been used to treat 25+
different types of cancer. By launching a basket oncology trial to study the
impact of the Hemopurifier on a variety of cancerous tumors, AEMD believes it
can generate data to support the Hemopurifier’s ability to improve outcomes,
when combined with checkpoint inhibitor treatment, in multiple tumor types
where cancer associated extracellular vesicles may promote immune suppression
and resistance to anti-PD-1 antibodies. Given the Hemopurifier’s demonstrated
ability to remove exosomes, management believes the device can be used to
affect improved outcomes in a number of cancers.
Moreover, by focusing on multiple cancers, the company has also expanded
the opportunities for patient enrollment, as well as for building a database to
support regulatory approval. By including both Keytruda and Opdivo can also
facilitate patient enrollments.
About Aethlon Medical, Inc. (NASDAQ:AEMD)
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening viral infections
and for use in organ transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful exosomes from
blood utilizing its proprietary lectin-based technology. This action has
potential applications in cancer, where exosomes may promote immune suppression
and metastasis, and in life-threatening infectious diseases. The Hemopurifier
is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in the
development or severity of the disease. The Hemopurifier also holds an FDA
Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are
not addressed with approved therapies.
About
Investorideas.com - Big Investing Ideas
Investorideas.com is a platform for
investing ideas. We publish
breaking stock news, stock research, guest posts and create original top rated
investing podcasts, plus sector tag articles featuring up and coming companies
and industry leaders. Investor Idea’s
original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
We also create
free investor stock directories for AI and tech, biotech, cannabis, cleantech,
crypto, defense, gaming, health and wellness, mining, oil and gas, sports and
water.
Public companies within the sectors we
cover can use our news publishing and content creation services to help tell
their story to interested investors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid
featured stock on Investorideas.com More disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences
Like Biotech Stocks? View our Biotech
Stocks Directory
Get News
Alerts on Biotech Stocks
